Favorable response to PD-1 receptor inhibitor pembrolizumab as a third-line therapy in ROS1-rearranged advanced lung cancer: A case report and review of the literature
ROS chromosomal rearrangements, which compromise around 1-2% of non-small cell carcinomas, have become an established therapeutic target. While targeted therapy for this mutation usually includes tyrosine kinase inhibitors such as crizotinib or alectinib, we present a unique case of a patient with s...
Main Authors: | Akriti Chaudhry, Kyle Schuppe, Skyler Burke, Veronika Lobova, Quincy Seigel, Carsten Kirby, Sara Chitlik, Mirela Andrei, Erin Kaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-12-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000540 |
Similar Items
-
Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01) -
Investigation of Molecular Interactions Mechanism of Pembrolizumab and PD-1
by: Simiao Wang, et al.
Published: (2023-06-01) -
Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review
by: Giulio Rizzetto, et al.
Published: (2023-08-01) -
Pembrolizumab-Induced Nasal Polyposis: The First Reported Case
by: Justin M. Hintze, et al.
Published: (2023-07-01) -
Pembrolizumab-Related Side Effects: Acute Renal Failure and Severe Neurological Toxicity
by: Gabriele Fasano, et al.
Published: (2022-01-01)